Ellen Puré

Title: Ellen Puré: Innovator in Cancer Research

Introduction

Ellen Puré is a prominent inventor based in Bryn Mawr, PA (US), known for her significant contributions to the field of cancer research. She holds a total of 6 patents that focus on innovative approaches to targeting fibroblast activation protein (FAP) in tumor tissues.

Latest Patents

One of her latest patents is a monoclonal antibody against canine fibroblast activation protein that cross-reacts with mouse and human fibroblast activation protein (FAP). This invention relates to antibodies, binding polypeptides, and scFvs specific for FAP, capable of cross-reacting with canine, mouse, and human FAP. Another notable patent involves disrupting tumor tissues by targeting fibroblast activation protein (FAP). This invention includes compositions and methods comprising a chimeric antigen receptor (CAR) that binds FAP for use in treating diseases, disorders, or conditions associated with the expression of FAP on canine, mouse, or human tumor-associated cells.

Career Highlights

Ellen Puré is affiliated with the University of Pennsylvania, where she continues her research and development in the field of immunology and cancer treatment. Her work has been instrumental in advancing the understanding of FAP and its role in tumor biology.

Collaborations

Ellen has collaborated with notable colleagues, including Leslie Todd and Steven A Albelda, to further her research initiatives and enhance the impact of her inventions.

Conclusion

Ellen Puré's innovative work in cancer research exemplifies the importance of targeting specific proteins in the treatment of tumors. Her contributions through her patents are paving the way for new therapeutic strategies in oncology.